161 related articles for article (PubMed ID: 23204176)
1. The beneficial effects of neuraminidase inhibitor drug therapy on severe patient outcomes during the 2009-2010 influenza A virus subtype H1N1 pandemic.
Aoki FY; Hayden FG
J Infect Dis; 2013 Feb; 207(4):547-9. PubMed ID: 23204176
[No Abstract] [Full Text] [Related]
2. [Neuraminidase inhibitors - lessons from the swine flu].
Markun S
Praxis (Bern 1994); 2013 May; 102(11):687-8. PubMed ID: 23692909
[No Abstract] [Full Text] [Related]
3. Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009-2010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients.
Muthuri SG; Myles PR; Venkatesan S; Leonardi-Bee J; Nguyen-Van-Tam JS
J Infect Dis; 2013 Feb; 207(4):553-63. PubMed ID: 23204175
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase inhibitors were widely used in the UK during the 2009 influenza A(H1N1) pandemic.
Nguyen-Van-Tam JS; Nicholson KG
J Clin Virol; 2011 Feb; 50(2):183. PubMed ID: 21112812
[No Abstract] [Full Text] [Related]
5. Supply of neuraminidase inhibitors related to reduced influenza A (H1N1) mortality during the 2009-2010 H1N1 pandemic: an ecological study.
Miller PE; Rambachan A; Hubbard RJ; Li J; Meyer AE; Stephens P; Mounts AW; Rolfes MA; Penn CR
PLoS One; 2012; 7(9):e43491. PubMed ID: 22984431
[TBL] [Abstract][Full Text] [Related]
6. Antivirals for pandemic influenza: a triumph of policy over evidence?
Thompson M; Heneghan C
Trends Pharmacol Sci; 2010 Sep; 31(9):391-3. PubMed ID: 20573406
[No Abstract] [Full Text] [Related]
7. Effectiveness of neuraminidase inhibitors for severe influenza.
Fry AM
Lancet Respir Med; 2014 May; 2(5):346-8. PubMed ID: 24815800
[No Abstract] [Full Text] [Related]
8. Prompt use of neuraminidase inhibitors improves survival of children severely ill with flu.
McCarthy M
BMJ; 2013 Nov; 347():f7127. PubMed ID: 24285175
[No Abstract] [Full Text] [Related]
9. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Wolkewitz M; Schumacher M
Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
[No Abstract] [Full Text] [Related]
10. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
[No Abstract] [Full Text] [Related]
11. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Jones M; Del Mar C; Hama R
Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
[No Abstract] [Full Text] [Related]
12. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
Antes G; Meerpohl JJ
Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
[No Abstract] [Full Text] [Related]
13. Global transmission of oseltamivir-resistant influenza.
Moscona A
N Engl J Med; 2009 Mar; 360(10):953-6. PubMed ID: 19258250
[No Abstract] [Full Text] [Related]
14. Comparison of the clinical symptoms and the effectiveness of neuraminidase inhibitors for patients with pandemic influenza H1N1 2009 or seasonal H1N1 influenza in the 2007-2008 and 2008-2009 seasons.
Kawai N; Ikematsu H; Tanaka O; Matsuura S; Maeda T; Yamauchi S; Hirotsu N; Nishimura M; Iwaki N; Kashiwagi S
J Infect Chemother; 2011 Jun; 17(3):375-81. PubMed ID: 21120678
[TBL] [Abstract][Full Text] [Related]
15. The truth about Tamiflu? Neuraminidase inhibitors in pandemic A/H1N1 flu.
Weber JT; Nicoll A; Bridges CB; Ciancio BC
BMJ; 2010 Jan; 340():c130. PubMed ID: 20071425
[No Abstract] [Full Text] [Related]
16. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
[TBL] [Abstract][Full Text] [Related]
17. Use of neuraminidase inhibitors in primary health care during pandemic and seasonal influenza between 2009 and 2013.
Blanchon T; Geffrier F; Turbelin C; Daviaud I; Laouénan C; Duval X; Lambert B; Hanslik T; Mosnier A; Leport C
Antivir Ther; 2015; 20(7):753-61. PubMed ID: 25687219
[TBL] [Abstract][Full Text] [Related]
18. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
[TBL] [Abstract][Full Text] [Related]
19. Antiviral treatment for patients hospitalized with 2009 pandemic influenza A (H1N1).
Uyeki T
N Engl J Med; 2009 Dec; 361(23):e110. PubMed ID: 19923564
[No Abstract] [Full Text] [Related]
20. Neuraminidase Inhibitors and Hospital Mortality in British Patients with H1N1 Influenza A: A Re-Analysis of Observational Data.
Wolkewitz M; Schumacher M
PLoS One; 2016; 11(9):e0160430. PubMed ID: 27583403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
